Mount Sinai has become the first hospital to implement FloPatch, a wearable device designed by Canada-based Flosonics Medical to monitor blood flow in its intensive care units (ICU).
The FloPatch enables ICU clinicians to perform haemodynamic assessments to guide intravenous (IV) fluid management and mitigate issues arising from excess fluid intake for patients with conditions such as sepsis, and in post-surgical care, wherein fluid boluses are often used to treat hypotension.
Post-surgery, many patients are not fluid responsive and may face adverse effects from unnecessary fluids, leading to complications and longer hospital stays. The provision of unnecessary fluids to patients post-surgery can include pulmonary oedema, heart failure, and abdominal compartment syndrome. Research indicates that impair tissue healing, thereby heightening the risk of wound infections and anastomotic leakage.
FloPatch received 510(k) clearance from the US Food and Drug Administration (FDA) in 2023.
Since introducing FloPatch, Mount Sinai clinicians have reportedly used it to bring greater precision to fluid therapy, moving 鈥渂eyond protocolised care to personalised decisions grounded in real-time patient data鈥�. According to early internal data from the hospital, 42% of patients assessed with FloPatch since its introduction were found to be unresponsive to fluids.
Dr John Oropello, professor of surgery and medicine at the Icahn School of Medicine at Mount Sinai and director of the transplant ICU at Mount Sinai, commented: 鈥淭he wireless ultrasound device addresses a longstanding need in critical care for accessible and repeatable assessments to understand a patient鈥檚 fluid responsiveness at the bedside. It allows our team to make timely, physiologically guided decisions in complex, high-acuity situations.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn March 2025, Flosonics completed a C$7.5m ($5.18m) venture debt fundraising round from financial solutions provider RBCx to expedite the wearable in the market. The device company added that its device鈥檚 adoption by Mount Sinai, which follows rollouts by healthcare systems, including California-based Sutter Health and Riverside University Health System, marks its first on the US East Coast.
According to GlobalData analysis, the overall global patient monitoring segment, of which Flosonics鈥� wearable is a part, will reach a valuation of around $25.6bn by 2034, up from $21.4bn in 2024.
